These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Drug, DME firms expect to get benefits from GATT. Gardner J Mod Healthc; 1994 Dec; 24(49):8. PubMed ID: 10138663 [No Abstract] [Full Text] [Related]
12. Indian biogenerics industry emerges. Jayaraman KS Nat Biotechnol; 2003 Oct; 21(10):1115-6. PubMed ID: 14520378 [No Abstract] [Full Text] [Related]
13. Pharmaceutical patents and some international trade issues: Canada, the United States, and NAFTA. Tancer RS Clin Ther; 1993; 15(6):1177-84; discussion 1120. PubMed ID: 8111813 [TBL] [Abstract][Full Text] [Related]
14. Patent threat in emerging economies shifts to biotech. Jayaranam K Nat Biotechnol; 2008 May; 26(5):481-3. PubMed ID: 18464760 [No Abstract] [Full Text] [Related]
15. . . . and Brazilian AIDS programme threatened by US trade action. Int J Epidemiol; 2001 Apr; 30(2):413. PubMed ID: 11369751 [No Abstract] [Full Text] [Related]
16. The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution? Silbermann JM J Contemp Health Law Policy; 1996; 12(2):607-36. PubMed ID: 8666736 [No Abstract] [Full Text] [Related]
18. IP litigation in China could drive innovation. Jia H Nat Biotechnol; 2004 Apr; 22(4):368. PubMed ID: 15060539 [No Abstract] [Full Text] [Related]
19. Discussions in Geneva, demonstrations in Delhi: why incentives for drug innovation need reviewing. Ford N; 't Hoen E; von Schoen-Angerer T Drug Discov Today; 2007 May; 12(9-10):349-51. PubMed ID: 17467570 [No Abstract] [Full Text] [Related]
20. An audience with... Robert R Ruffolo, Jr. Interview by Joanna Owens. Ruffolo RR Nat Rev Drug Discov; 2006 Sep; 5(9):714. PubMed ID: 17001801 [No Abstract] [Full Text] [Related] [Next] [New Search]